Month: December 2023

Preventogen is a New Tool in the Fight Against Antibiotic-Resistant Infections Caused by Superbugs, a Leading Cause of Death Worldwide

Preventogen's FDA-Cleared Microbicidal Liquid Polymer Ensures the Eradication of These Dangerous Pathogens on Contact While Forming a More Effective and...

eClinicalWorks Announces Intent to Become a Qualified Health Information Network and Further Enhance Nationwide Interoperability

eClinicalWorks successfully completes Phase 1 of the application process for QHIN designationWESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, the largest ambulatory cloud EHR, today...

Pressure BioSciences’ UltraShear Platform Maintains Nutritional, Sensory, and Other Important Qualities of Liquid Foods While Inactivating Foodborne Bacterial Spores

Novel Results Published in Respected Peer-Reviewed Food Science and Emerging Technologies Journal - Discussions Underway with Beverage Industry CompaniesSOUTH EASTON,...

“Stemtech’s Annual Incentive Cruise Sets Sail With Top Earners on Board; Colombia Pre-Registration Now Open and Product Expansion Unveiled for Ecuador”

Before the REORGANIZATION, Stemtech thrived IN COLOMBIA, generating $10 million and boasting 3,000 IBPs in the Colombian market.NAPLES, FL /...

Orthofix Announces Agreement with Engine Capital and Appointment of Three New Independent Directors to Further Advance Position as Leading Global Spine and Orthopedics Company

Three New Directors Bring Substantial Finance, Strategic Development, Healthcare and MedTech ExperienceLEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ: OFIX) (“Orthofix” or...

Orthofix Announces Agreement with Engine Capital and Appointment of Three New Independent Directors to Further Advance Position as Leading Global Spine and Orthopedics Company

Three New Directors Bring Substantial Finance, Strategic Development, Healthcare and MedTech ExperienceLEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ: OFIX) (“Orthofix” or...

Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals

Long term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new...

error: Content is protected !!